ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour

Dr César Serrano speaks to ecancer about the circulating tumour DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumour (GIST).

He outlines the methodology and processes involved in the VOYAGER trial.

The results showed hybrid capture-based plasma sequencing detects ctDNA in the majority of patients with advanced TKI-resistant GIST, including heterogeneity of KIT mutations. This study is the first to show that ctDNA sequencing correlates with outcomes in pretreated GIST.

Dr Seranno concludes by summarising the current and future impact of these findings.